Literature DB >> 17910642

Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera.

Linda M Scott, Philip A Beer, Anthony J Bench, Wendy N Erber, Anthony R Green.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17910642     DOI： 10.1111/j.1365-2141.2007.06806.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

Review 1.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

2.  Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study.

Authors:  François Girodon; Gilles Bonicelli; Céline Schaeffer; Morgane Mounier; Serge Carillo; Ingrid Lafon; Paule Marie Carli; Inès Janoray; Emmanuelle Ferrant; Marc Maynadié
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

3.  Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.

Authors:  Ana Paula Azevedo; Susana N Silva; Alice Reichert; Fernando Lima; Esmeraldina Júnior; José Rueff
Journal:  Biomed Rep       Date:  2017-09-05

4.  Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations--clinical relevance in the monitoring of polycythemia.

Authors:  Serge Carillo; Laurent Henry; Eric Lippert; François Girodon; Isabelle Guiraud; Céline Richard; Frédérique Dubois Galopin; Cedric Cleyrat; Eric Jourdan; Robert Kralovics; Sylvie Hermouet; Thierry Lavabre-Bertrand
Journal:  J Mol Diagn       Date:  2011-05       Impact factor: 5.568

5.  JAK2 V617F and the evolving paradigm of polycythemia vera.

Authors:  Robert T Means
Journal:  Korean J Hematol       Date:  2010-06-30

6.  STAT1 activation in association with JAK2 exon 12 mutations.

Authors:  Anna L Godfrey; Edwin Chen; Charles E Massie; Yvonne Silber; Francesca Pagano; Beatriz Bellosillo; Paola Guglielmelli; Claire N Harrison; John T Reilly; Frank Stegelmann; Fontanet Bijou; Eric Lippert; Jean-Michel Boiron; Konstanze Döhner; Alessandro M Vannucchi; Carlos Besses; Anthony R Green
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

7.  Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms.

Authors:  Joseph Tripodi; Ronald Hoffman; Vesna Najfeld; Rona Weinberg
Journal:  Cancer Manag Res       Date:  2010-09-17       Impact factor: 3.989

8.  Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1.

Authors:  Nicholas P D Liau; Artem Laktyushin; Rhiannon Morris; Jarrod J Sandow; Nicos A Nicola; Nadia J Kershaw; Jeffrey J Babon
Journal:  Cancers (Basel)       Date:  2019-11-01       Impact factor: 6.639

Review 9.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.